… evaluate the clinical impact of a single routine measurement of Lp(a) on cardiovascular
disease (CVD) risk reclassification and the potential implications for guideline-based preventive …

Elevated levels of low-density lipoprotein cholesterol (LDL-C) are associated with increased
risk of coronary heart disease and stroke. Guidelines for the management of dyslipidaemia …

… In this review, we evaluate the causal role of Lp(a) across the cardiovascular disease spectrum,
examine the role of established lipid-modifying therapies in lowering Lp(a), and focus on …

… LDL cholesterol targets in the primary prevention setting. When evaluating LDL cholesterol
targets for patients treated for primary and secondary prevention, Lp(a) concentrations might …

… The treatment of dyslipidemias plays a major role in the primary and secondary prevention
of cardiovascular disease. Proper evaluation of the patient’s lipid status is very important for …

… in terms of primary prevention, as well as in the secondary prevention of cardiovascular …
evaluated in studies currently in progress, with promising results so far. The future management …

… of ASCVD prevention is the harmonization of serum lipid and lipoprotein profiles produced …
on the quantification of atherogenic lipoproteins in nonfasting and fasting blood samples [1], [2…

Importance The association between statin-induced reduction in low-density lipoprotein
cholesterol (LDL-C) levels and the absolute risk reduction of individual, rather than composite, …

… of ASCVD prevention is the harmonisation of serum lipid and lipoprotein profiles produced …
on the quantification of atherogenic lipoproteins in nonfasting and fasting blood samples [1,2]. …

Evidence from Mendelian randomization studies suggest that lipoprotein(a) (Lp(a)) has a
causal role in the development of atherosclerotic cardiovascular disease risk. However, …